FDA Approves Pfizer Vaccine to Protect Newborns from Respiratory Syncytial Virus (RSV)
- 23 Aug 2023
On 21st August, the US Food and Drug Administration (FDA) granted approval for the first vaccine designed to safeguard newborns from Respiratory Syncytial Virus (RSV).
Key Points:
- Protection for Newborns: Pfizer's newly approved vaccine is intended to safeguard newborns by administering it to mothers during the latter stages of pregnancy.
- This approach ensures protection for infants during their critical first six months of life.
- Trial Results: Clinical trials involving over 7,000 pregnant individuals and their infants demonstrated that the vaccine significantly reduced the likelihood of infants requiring medical attention and also decreased instances of infant hospitalization.
- Understanding RSV: Respiratory Syncytial Virus (RSV) primarily affects the lungs and respiratory tract, posing a significant risk to children and the elderly.
- It often leads to numerous hospitalizations, with the most severe impact typically occurring during the winter months.
- The recent RSV season was unusually long and severe, straining children's hospitals.
- FDA Director's Statement: The vaccine provides an essential option for healthcare providers and expectant individuals to protect infants from this potentially life-threatening disease.
- Multiple RSV Vaccines: Various vaccines are available to protect individuals from RSV.
- The recently approved antibody shot is specifically designed to safeguard infants after birth from the virus.
- Additionally, there are new vaccines accessible for individuals aged 60 and older.
